GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2024-08-01 Epub Date: 2024-05-29 DOI:10.1007/s11883-024-01214-6

Javeria Hayat, Nishant P Shah, Anandita Agarwala, Muhammad Shahzeb Khan, Javed Butler

{"title":"GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?","authors":"Javeria Hayat, Nishant P Shah, Anandita Agarwala, Muhammad Shahzeb Khan, Javed Butler","doi":"10.1007/s11883-024-01214-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining importance due to their effects on cardiovascular parameters. This review discusses the findings of dedicated cardiovascular outcome trials of GLP-1RAs and summarizes their utility to help clinicians understand their role in cardiovascular disease.Recent findings: Patients with diabetes mellitus are at an increased risk of cardiovascular disease. Cardiovascular outcome trials have shown GLP-1RAs decrease the primary composite outcome of the first occurrence of major adverse cardiovascular events (MACE) in patients with diabetes. Additionally, select GLP-1RAs have also shown improved cardiovascular outcomes in patients without diabetes who are either overweight (BMI ≥ 27), or obese (BMI ≥ 30). There have also been encouraging results in patients with heart failure with preserved ejection fraction. There is increasing evidence showing GLP-1RAs are beneficial across the cardiometabolic spectrum of disease. Implementation of these therapeutics into clinical practice is important to improve cardiovascular risk.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"341-351"},"PeriodicalIF":5.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-024-01214-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining importance due to their effects on cardiovascular parameters. This review discusses the findings of dedicated cardiovascular outcome trials of GLP-1RAs and summarizes their utility to help clinicians understand their role in cardiovascular disease.

Recent findings: Patients with diabetes mellitus are at an increased risk of cardiovascular disease. Cardiovascular outcome trials have shown GLP-1RAs decrease the primary composite outcome of the first occurrence of major adverse cardiovascular events (MACE) in patients with diabetes. Additionally, select GLP-1RAs have also shown improved cardiovascular outcomes in patients without diabetes who are either overweight (BMI ≥ 27), or obese (BMI ≥ 30). There have also been encouraging results in patients with heart failure with preserved ejection fraction. There is increasing evidence showing GLP-1RAs are beneficial across the cardiometabolic spectrum of disease. Implementation of these therapeutics into clinical practice is important to improve cardiovascular risk.

Abstract Image

查看原文本刊更多论文

GLP-1 受体激动剂与心血管疾病：临床医生需要了解什么？

综述目的：胰高血糖素样肽-1受体激动剂（GLP-1RAs）因其对心血管参数的影响而日益受到重视。本综述讨论了专门针对 GLP-1RAs 的心血管结果试验结果，并总结了它们的效用，以帮助临床医生了解它们在心血管疾病中的作用：最新发现：糖尿病患者罹患心血管疾病的风险增加。心血管研究结果表明，GLP-1RA 可降低糖尿病患者首次发生主要不良心血管事件 (MACE) 的主要综合结果。此外，对于体重超重（体重指数≥ 27）或肥胖（体重指数≥ 30）的非糖尿病患者，精选的 GLP-1RA 也能改善心血管预后。在射血分数保留的心力衰竭患者中也取得了令人鼓舞的结果。越来越多的证据显示，GLP-1RAs 可用于治疗各种心脏代谢疾病。将这些疗法应用于临床实践对于改善心血管风险非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.